The New Valeant Model
This article was originally published in RPM Report
This sounds like a winning formula for the biopharma industry in the current climate: voluntarily adopt greater transparency, increase R&D spending and promise restraint on pricing. But is Valeant really the right company to lead the way?
Register for our free email digests: